成纤维细胞激活蛋白α与肿瘤微环境的免疫抑制
作者：邓媛媛;徐俊;杨倩之;蔡绍晖;
Author：
收稿日期： 年卷（期）页码：2012,27(04):-455-457
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：成纤维细胞激活蛋白α;肿瘤微环境;免疫抑制;靶向治疗
Key words：
基金项目：国家自然科学基金资助项目(批准号:30973565)
中文摘要
成纤维细胞激活蛋白α(FAPα)是肿瘤微环境中特异性表达于肿瘤相关成纤维细胞(TAF)表面的抗原分子,属丝氨酸蛋白酶家族Ⅱ型膜整合糖蛋白,具有二肽酶和胶原酶活性,对肿瘤微环境的免疫抑制和肿瘤浸润转移有重要作用。因此,FAPα已被视为理想的肿瘤治疗靶标。本文综述了FAPα阳性细胞对肿瘤微环境免疫抑制状态的形成及靶向FAPα治疗的研究。
参考文献
[1]Fidler IJ.The pathogenesis of cancer metastasis:The seed and soilhypothesis revisited[J].Nat Rev Canc,2003,3(6):453-458.
[2]Fearon DT,Kraman M,Bambrough PJ,et al.Suppression of anti-tumor immunity by stromal cells expressing fibroblast activationprotein-alpha[J].Sci,2010,330(6005):827-830.
[3]Cheng JD,Weiner LM.Tumors and their microenvironrilents:Tilling the soil[J].Clin Canc Res,2003,9(5):1590-1595.
[4]Tabi Z,Man S.Challenges for cancer vaccine development[J].Adv Drug Deliv Rev,2006,58(8):902-915.
[5]Joyce JA,Pollard JW.Microenvironmental regulation of metastasis[J].Nat Rev Canc,2009,9(4):239-252.
[6]Vasievich EA,Huang L.The suppressive tumor microenviron-ment:A challenge in cancer immunotherapy[J].Mol Pharmac,2011,8(3):635-641.
[7]Nomura T,Sakaguchi S.Naturally arising CD25+CD4+regulato-ry T cells in tumor immunity[J].Curr Top Microbiol Immunol,2005:287-302.
[8]Chalmin F,Ladoire S,Mignot G,et al.Membrane-associatedHsp72 from tumor-derived exosomes mediates STAT3-depend-ent immunosuppressive function of mouse and human myeloid-derived suppressor cells[J].J Clin Invest,2010,120(2):457-471.
[9]Liu Z,Kim JH,Falo LD,et al.Tumor regulatory T cells potentlyabrogate antitumor immunity[J].J Immun,2009,182(10):6160-6167.
[10]Fusenig NE,Mueller MM.Friends or foes-bipolar effects of thetumour stroma in cancer[J].Nat Rev Canc,2004,4(11):839-849.
[11]Schreiber H,Rowley DA.Awakening immunity[J].Sci,2010,330(6005):761-762.
[12]Chang HY,Sneddon JB,Alizadeh AA,et al.Gene expression sig-nature of fibroblast serum response predicts human cancer pro-gression:Similarities between tumors and wounds[J].PLos Biol,2004,2(2):E7.
[13]Huber MA,Kraut N,Park JE,et al.Fibroblast activation protein:Differential expression and serine protease activity in reactivestromal fibroblasts of melanocytic skin tumors[J].J Invest Der-mat,2003,120(2):182-188.
[14]Acharya PS,Zukas A,Chandan V,et al.Fibroblast activation pro-tein:A serine protease expressed at the remodeling interface in id-iopathic pulmonary flbrosis[J].Human Pathology,2006,37(3):352-360.
[15]Gorrell MD,Ajami K,Abbott CA,et al.Structural requirementsfor catalysis,expression,and dimerization in the CD26/DPIVgene family[J].Biochem,2003,42(3):694-701.
[16]Ostman A,Augsten M.Cancer-associated fibroblasts and tumorgrowth-bystanders turning into key players[J].Curr Opin GenetDevelop,2009,19(1):67-73.
[17]Kryczek I,Wei S,Keller E,et al.Stroma-derived factor(SDF-1/CXCL12)and human tumor pathogenesis[J].Am J PhysiolCell Physiol,2007,292(3):C987-995.
[18]Pfizenmaier K,Schmidt A,Muller D,et al.Generation of humanhigh-affinity antibodies specific for the fibroblast activation pro-tein by guided selection[J].Eur J Biochem,2001,268(6):1730-1738.
[19]Loeffler M,Kruger JA,Niethammer AG,et al.Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasingintratumoral drug uptake[J].J Clin Invest,2009,119(2):421-421.
[20]Yi YM,Zhang G,Zeng J,et al.A new tumor vaccine:FAPtau-MT elicits effective antitumor response by targeting indolamine2,3-dioxygenase in antigen presenting cells[J].Canc Bio Ther,2011,11(10):866-873.
[21]Edosada CY,Quan C,Wiesmann C,et al.Selective inhibition offibroblast activation protein protease based on dipeptide substratespecificity[J].J Biol Chem,2006,281(11):7437-7444.
[22]Cheng JD,Narra K,Mullins SR,et al.Phase II trial of single agentVal-boroPro(Talabostat)inhibiting fibroblast activation proteinin patients with metastatic colorectal cancer[J].Canc Bio Ther,2007,6(11):1691-1699.
[23]Jones B,Adams S,Miller GT,et al.Hematopoietic stimulation bya dipeptidyl peptidase inhibitor reveals a novel regulatory mecha-nism and therapeutic treatment for blood cell deficiencies[J].Blood,2003,102(5):1641-1648.
[24]Dalle S,Thieblemont C,Thomas L,et al.Monoclonal antibodies inclinical oncology[J].Anti-Cancer Agents Med Chem,2008,8(5):523-532.
【关闭】
